Skip to main content

Search

Reset all filters
491 Result(s)
Sort by

Our Partners_ViraTherapeutics

Our Partners_ViraTherapeutics

Lisa Egerer, COO and Patrik Erlman, Head of Research at ViraTherapeutics talk about their partnering journey with Boehringer Ingelheim.
Obesity osteoarthritis in pets a blind spot

Obesity osteoarthritis in pets a blind spot

Same as with humans, body weight is just one indicator among many when it comes to a pet’s health status. However, there are some diseases associated with it. Learn more here.
Protein Degraders in Cancer

Protein Degraders in Cancer

Boehringer Ingelheim scientists and their partners are exploring how protein degraders could bring so-called undruggable cancer targets within reach
Stargardt Disease

Stargardt Disease

Stargardt Disease is a hereditary condition causing and progressive vision loss, typically during childhood or adolescence.
Understanding heart failure

Understanding heart failure

Heart failure is a complicated clinical condition which affects more than 60 million people worldwide. Find out more about the condition here.
COVID-19 Ivermectin Animal Health Not for Human Use

COVID-19 Ivermectin Animal Health Not for Human Use

Boehringer Ingelheim manufactures several veterinary products containing ivermectin. They are not approved or suitable for use in humans to try to prevent or treat COVID-19.
SIRPα Cancer Immunology Research

SIRPα Cancer Immunology Research

Boehringer Ingelheim scientists are investigating a new target in the innate immune system - signal-regulating protein alpha or SIRPα.
Advancing regenerative medicine

Advancing regenerative medicine

Strategic partnerships play a key role in helping the company accelerate the next generation of breakthroughs.
Bees and biodiversity

Bees and biodiversity

At Boehringer Ingelheim we attach great importance to sustainable planting on our company site – and to protecting the bees.
Waste

Waste

Resource conservation at Boehringer Ingelheim is managed as part of an ongoing process of prevention and reduction of material usage and waste.
EHS management approach

EHS management approach

We protect our employees, facilities and the environment from harmful influences, conserve natural resources and promote environmental awareness
Patient Organizations

Patient Organizations

Boehringer Ingelheim’s core principles and vision guide our work with patient organisations.
Performance Indicators

Performance Indicators

Performance indicators concerning Environment Health and Safety (EHS) are summarized here.
Expectations towards our business partners

Expectations towards our business partners

We utilize an extensive network of international suppliers for procuring raw materials, intermediates, packaging materials, technical components and services to deliver our innovative medications worldwide.